Cyclin-dependent kinase 9 (CDK9) (CDK9)

Cyclin-dependent kinase 9 (CDK9) is the catalytic subunit of the positive transcription elongation factor b (P-TEFb) complex, which is essential for the regulation of eukaryotic gene transcription [1]. Unlike cell cycle-related CDKs, CDK9 primarily functions to promote the transition of RNA polymerase II (RNAP II) from promoter-proximal pausing to productive elongation by phosphorylating the Ser2 residues of the RNAP II C-terminal domain (CTD) [2]. This mechanism is particularly vital for the expression of short-lived proteins, including key oncogenes like MYC and anti-apoptotic factors such as MCL-1 [3]. In many cancers, CDK9 is overexpressed or hyperactivated, leading to the sustained survival of malignant cells and resistance to apoptosis [4]. Consequently, CDK9 has emerged as a significant therapeutic target, with several small-molecule inhibitors currently in clinical development for hematologic malignancies and solid tumors [5]. Beyond oncology, CDK9 is also a critical factor in viral replication, notably for HIV-1, where it is recruited by the viral Tat protein to enhance viral gene expression [6]. Therapeutic strategies focusing on CDK9 inhibition aim to selectively induce apoptosis in cancer cells by depleting critical survival factors that the cells are 'addicted' to [5, 8]. Clinical challenges include managing systemic toxicities and achieving high selectivity to avoid interfering with the broader roles of other cyclin-dependent kinases [9].

Other names

Positive transcription elongation factor b (P-TEFb) catalytic subunitPITALREC-terminal domain kinaseCell division cycle 2-like protein kinase 4 (CDC2L4)Tat-associated kinase (TAK)

Inhibition of CDK9 kinase activity within the P-TEFb complex prevents the phosphorylation of Serine 2 in the C-terminal domain of RNA polymerase II, which blocks the transition from transcription initiation to productive elongation and selectively reduces the expression of short-lived oncogenic and anti-apoptotic proteins [2, 5].